Senolytics: dasatinib, quercetin, and the human data

Key takeaways

• Senolytics selectively kill senescent cells. The lead program is the dasatinib + quercetin (D+Q) combination identified at Mayo Clinic and Scripps by Zhu et al. 2015 .
• The IPF pilot (Justice et al. 2019, 14 subjects, open-label) showed significant short-term physical-function gains ; the diabetic-kidney pilot (Hickson et al. 2019, 9 subjects) showed reduced senescent-cell burden on adipose biopsy .
• Dasatinib (Sprycel) is FDA-approved for chronic myeloid leukemia and Ph+ ALL at 100 to 140 mg once daily continuous dosing, with a substantial labeled adverse-event burden (pleural effusion, cardiac dysfunction, myelosuppression) .
• Senolytic dosing is intermittent (about 100 mg dasatinib for 2 to 3 days, e.g. 2 days on then 14 off in the Alzheimer's pilot); long-term safety of repeated pulses is not characterized in any published trial .
• Unity Biotechnology's UBX0101 (intra-articular MDM2-p53 senolytic) missed its primary pain endpoint in a 183-patient phase 2 knee-osteoarthritis trial, and Unity dropped the program in 2020 .

What senescent cells are, and why they matter

Cellular senescence is a state of stable cell-cycle arrest with a distinctive secretory program, the senescence-associated secretory phenotype (SASP): pro-inflammatory cytokines, chemokines, growth factors, and matrix-remodeling enzymes. Senescent cells accumulate with age, and their SASP contributes to chronic low-grade inflammation, impaired tissue regeneration, and age-related disease .

The senolytic hypothesis is that clearing senescent cells pharmacologically reduces their pathological contribution to aging tissue. Foundational mouse work by Baker and colleagues (2011, 2016) used the INK-ATTAC genetic model to selectively kill p16-positive cells and reported improved healthspan and a modest extension of median lifespan. The drug program then asked whether small molecules could do the same .

How D+Q was found (Zhu et al. 2015)

Zhu and colleagues (2015) at Mayo Clinic and Scripps screened compounds for senolytic activity in cultured senescent cells. Dasatinib (a tyrosine kinase inhibitor approved for chronic myeloid leukemia) cleared senescent fat-cell progenitors; quercetin (a flavonoid) was more effective against senescent endothelial cells; the combination (D+Q) cleared senescent cells more broadly than either alone .

The same work reported reduced senescent-cell burden and improved cardiac function and exercise capacity in aged mice, which is what motivated the first human pilots .

The Justice IPF pilot (2019): 14 subjects, function up

Justice and colleagues (2019) ran a first-in-human, open-label, single-arm pilot of D+Q in 14 adults with idiopathic pulmonary fibrosis (IPF), an age-associated disease where senescent fibroblasts and alveolar epithelial cells are implicated. Subjects took dasatinib 100 mg plus quercetin 1250 mg for 3 consecutive days per week, for 3 weeks. Physical-function endpoints (6-minute walk distance, 4-meter gait speed, chair-stand time) improved significantly over the short follow-up; pulmonary function did not change .

Caveats: 14 subjects, no placebo arm, short duration, surrogate endpoints. The result fits the preclinical hypothesis but is hypothesis-generating, and the trial was not designed to test mortality or hard pulmonary outcomes.

The Hickson diabetic-kidney pilot (2019): cells cleared

Hickson and colleagues (2019) ran a separate open-label D+Q pilot in 9 adults with diabetic kidney disease: a single 3-day course of dasatinib 100 mg plus quercetin 1000 mg, then adipose and skin biopsies 11 days later. The biopsy showed reduced senescent-cell burden (about a 35 percent drop in p16-positive cells in adipose tissue, with p21-positive cells and beta-galactosidase staining also down) and lower circulating SASP factors .

This is the closest published evidence that a single D+Q course actually clears senescent cells in human tissue. It was small, open-label, and biomarker-focused; it did not test clinical outcomes.

The wider D+Q program is small and surrogate-endpoint

Multiple D+Q trials are registered on ClinicalTrials.gov across age-related conditions, most of them small and using surrogate endpoints (senescence biomarkers, physical function, cognition) rather than mortality . One example is SToMP-AD, a University of Texas pilot of intermittent D+Q in early Alzheimer's disease that dosed 2 days on, 14 days off, over 12 weeks .

As of 2026, no large randomized D+Q trial with hard outcome endpoints in a healthy aging population has been published. The clinical program is progressing but remains pre-confirmatory.

Dasatinib (Sprycel): the label and intermittent-dose safety

Dasatinib is FDA-approved as Sprycel for chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia, dosed continuously at 100 to 140 mg once daily (100 mg for chronic-phase CML, 140 mg for advanced disease). The labeled adverse-event profile at continuous dosing is substantial :

• Pleural effusion (about 12 percent at 100 mg once daily in the newly diagnosed chronic-phase CML trial).
• Pulmonary arterial hypertension.
• Cardiac dysfunction (QT prolongation, congestive heart failure, ventricular dysfunction).
• Severe hemorrhage (CNS, GI), including fatalities.
• Myelosuppression (neutropenia, thrombocytopenia, anemia).
• Fluid retention beyond pleural effusion (pericardial effusion, ascites, generalized edema).

Senolytic protocols use intermittent dosing, so cumulative exposure is far below the continuous oncology dose. In the trials the pulses run about 100 mg dasatinib for 2 to 3 consecutive days, on a weekly-to-fortnightly cadence (the Alzheimer's pilot dosed 2 days on, 14 off) . The published senolytic pilots have not reported the full continuous-dosing adverse-event burden, but long-term safety across months to years of repeated pulses is not characterized in any published trial. If you are self-sourcing, the drug is still dasatinib: the labeled cardiopulmonary and bleeding risks are why oncology patients get regular blood counts and cardiac monitoring, and self-directed use skips exactly that monitoring.

Quercetin at the senolytic dose (1000 to 1500 mg) is an unusually high oral flavonoid load. Tolerability looks acceptable in the published trials, but long-term effects on iron absorption, kidney function, and CYP-substrate drug interactions are less studied than the drug component.

Fisetin: the alternate flavonoid senolytic

Fisetin, another flavonoid, was the most potent senolytic in a mouse flavonoid screen from the Niedernhofer and Robbins group (Yousefzadeh et al. 2018), which reported reduced senescent-cell markers and a modest lifespan extension in aged mice . It is now in human trials in older adults. Mayo Clinic's AFFIRM-LITE trial (phase 2) tests fisetin at 20 mg/kg/day for 2 days against placebo in frail older adults , and other fisetin trials are registered in conditions such as diabetic kidney disease and osteoarthritis . Published efficacy readouts are limited as of 2026; the program is at the same surrogate-endpoint stage as D+Q.

Fisetin is sold widely as a supplement at doses well below the trial dose. Whether supplement-dose fisetin produces meaningful senolytic activity in humans is not established. The trial dose is gram-scale (20 mg/kg/day works out to roughly 1400 mg for a 70 kg adult), a flavonoid load far above typical dietary intake.

The UBX0101 osteoarthritis program failure

Unity Biotechnology developed UBX0101, an MDM2-p53 senolytic, for intra-articular injection in knee osteoarthritis. The phase 2 trial (NCT04129944) randomized 183 patients to a single injection of placebo or UBX0101 at 0.5, 2.0, or 4.0 mg, with the WOMAC-A pain score at week 12 as the primary endpoint . Per Unity's own August 2020 announcement, no dose beat placebo on WOMAC-A at 12 weeks, and the company dropped the program . UBX0101 is a different molecule, tissue, and endpoint from D+Q, so the miss does not sink the senolytic hypothesis. It does show that a single senolytic course will not automatically move a clinical endpoint.

The senescence-quantification problem

There is no validated single-cell or single-blood-test biomarker for senescent-cell burden in humans. p16INK4a expression in T cells, circulating SASP cytokines, growth differentiation factor 15 (GDF15), and tissue biopsy with p16/p21/SASP staining are all imperfect proxies. Any single marker can move for non-senescent reasons (acute inflammation, infection, exercise), and the markers do not always track each other.

This is the core methodological problem for the field. Without a clean biomarker, trials fall back on functional endpoints (physical performance, disease-specific outcomes), which move slowly and noisily. The Hickson 2019 biopsy is the most direct demonstration of senescent-cell clearance in human tissue, but a biopsy does not scale to a large outcome trial .

What the trials do not answer

• Whether intermittent senolytic courses reduce mortality or hard age-related disease endpoints over multi-year follow-up.
• What the optimal interval between senolytic courses is.
• Whether D+Q, fisetin, or future senolytics differ meaningfully in tissue-specific clearance patterns.
• Whether the lack of a clean biomarker is hiding heterogeneity (responders vs non-responders).
• How the intermittent-dose long-term safety of dasatinib compares to continuous oncology dosing across years of repeat exposure.

Where senolytics actually stand

Senolytics in 2026 sit roughly where rapamycin sat in the early 2010s. The preclinical signal is strong. The human evidence is a few small open-label pilots plus one clean tissue-level demonstration (the Hickson 2019 biopsy) . What is missing is a large placebo-controlled trial with hard endpoints. The dasatinib safety profile at continuous dosing is real, and the intermittent-dosing rationale is plausible without being validated.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 13 entries, primary canon (PubMed, ClinicalTrials.gov, DailyMed) plus two ClinicalTrials.gov breadth searches and one company announcement acknowledged inline, last reviewed 2026-07-08.